Four weeks treatment for chronic hepatitis C in patients under 50 years of age with no significant liver fibrosis (Fire ugers behandling af kronisk leverbetændelse type C hos personer under 50 år, uden betydende arvæv i leveren)

Trial Profile

Four weeks treatment for chronic hepatitis C in patients under 50 years of age with no significant liver fibrosis (Fire ugers behandling af kronisk leverbetændelse type C hos personer under 50 år, uden betydende arvæv i leveren)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Glecaprevir/pibrentasvir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms 4 RIBC
  • Most Recent Events

    • 12 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top